Mirador Therapeutics Expands Precision Immunology Portfolio with Exclusive License to KP-301, a Long-Acting Anti-C5a AntibodyMirador Therapeutics, Inc. (Mirador), a clinical-stage precision medicine company developing next-generation therapies for immune-mediated inflammatory and fibrotic diseases, today announced that it has entered into an exclusive worldwide license agreement with Kira Pharmaceuticals (Kira) for KP-301, a potentially long-acting, sweeping anti-C5a antibody designed to inhibit C5a/C5aR-mediated inflammation, and other related intellectual property. The agreement expands Mirador’s precision immunology portfolio into inflammatory vascular disease, a therapeutic area with validated biology and significant unmet need.
Mirador Accelerates Multi-Asset Clinical Pipeline in Immuno-Fibrotic Disease; Closes $250 Million Series B with Premier Investors
Mirador Therapeutics, Inc. (Mirador), a clinical-stage precision medicine company developing next-generation therapies for immune-mediated inflammatory and fibrotic diseases, today announced key clinical updates and corporate progress.
Mirador Therapeutics Appoints Gregg Gilbert as Chief Financial Officer
Mirador Therapeutics, Inc., a next-generation precision medicine company focused on developing first-in-class or best-in-class therapeutics for immunology and inflammation (I&I), today announced the appointment of Gregg Gilbert as chief financial officer. Mr. Gilbert brings more than 25 years of leadership experience in biopharma equity research analysis and investment banking to the role.
Mirador Therapeutics Launches to Accelerate the Next Generation of Precision Medicines for Immune-mediated Diseases
Mirador Therapeutics, Inc. (Mirador) announced its launch today. Founded by Mark C. McKenna and led by several former executives of Prometheus Biosciences (acquired in 2023 by Merck for $10.8 billion), Mirador aims to revolutionize precision medicine for immune-mediated inflammatory and fibrotic diseases by leveraging its proprietary Mirador360TM development engine to rapidly advance multiple programs. Mirador has raised more than $400 million in financing led by ARCH Venture Partners, with early investments from OrbiMed and Fairmount. Other premier life sciences investors also participated, including Fidelity Management & Research Company, Point72, Farallon Capital Management, Boxer Capital, TCGX, Invus, Logos Capital, Moore Strategic Ventures, Blue Owl Healthcare Opportunities, Sanofi Ventures, Woodline Partners LP, Venrock Healthcare Capital Partners, RTW Investments and Alexandria Venture Investments.
